论文部分内容阅读
目的探讨多发性硬化(MS)患者血清尿酸(UA)及超敏C反应蛋白(hs-CRP)水平变化与病情活动性的关系。方法测定24例MS患者急性期及经鞘内注射甲基强的松龙治疗后缓解期血清UA及hs-CRP值,并与其他非炎症性神经系统疾病(NIND)作对照组,同时对比治疗前后神经功能缺损评分。结果 MS患者急性期血清UA水平显著低于缓解期及对照组。MS患者急性期血清hs-CRP水平显著高于缓解期及对照组,MS缓解期与对照组UA和hs-CRP水平无统计学差异。伴随着UA水平回升及hs-CRP水平下降,神经功能缺损评分降低,临床症状改善。结论血清UA及hs-CRP水平变化与MS患者病情活动密切相关,UA及hs-CRP可作为观察MS病情活动性及激素疗效的指标之一,升高血清UA水平及抗炎可能是一种有前途的治疗方法。
Objective To investigate the relationship between serum uric acid (UA) and hs-CRP in patients with multiple sclerosis (MS) and their disease activity. Methods Serum UA and hs-CRP levels were measured in 24 patients with MS at acute stage and after intrathecal methylprednisolone treatment, and compared with other noninflammatory neurological diseases (NIND) Before and after neurological deficit score. Results The serum level of UA in patients with acute MS was significantly lower than that in patients in remission and control group. The level of hs-CRP in acute phase of MS patients was significantly higher than that in remission and control group, while the levels of UA and hs-CRP in MS remission phase were not significantly different. With the recovery of UA and the decrease of hs-CRP level, the score of neurological deficit decreased and the clinical symptoms improved. Conclusions The changes of serum UA and hs-CRP levels are closely related to the severity of MS. UA and hs-CRP may be used as an index to observe the activity of MS and hormone therapy. Increasing serum UA level and anti-inflammatory may be a Future treatment.